MX366813B - Polipeptidos de enlace cd3. - Google Patents

Polipeptidos de enlace cd3.

Info

Publication number
MX366813B
MX366813B MX2014012578A MX2014012578A MX366813B MX 366813 B MX366813 B MX 366813B MX 2014012578 A MX2014012578 A MX 2014012578A MX 2014012578 A MX2014012578 A MX 2014012578A MX 366813 B MX366813 B MX 366813B
Authority
MX
Mexico
Prior art keywords
binding polypeptides
polypeptides
binding
num
Prior art date
Application number
MX2014012578A
Other languages
English (en)
Other versions
MX2014012578A (es
Inventor
Philip Huat Tan
Sateesh Kumar Natarajan
Catherine J Mcmahan
Original Assignee
Aptevo Res & Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Res & Development Llc filed Critical Aptevo Res & Development Llc
Publication of MX2014012578A publication Critical patent/MX2014012578A/es
Publication of MX366813B publication Critical patent/MX366813B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un polipéptido de enlace CD3 caracterizado porque comprende un dominio de enlace CD3, en donde el dominio de enlace CD3 tiene un punto isoeléctrico reducido en comparación con el punto isoleléctrico de un dominio de enlace con la secuencia de aminoácidos de SEQ ID NO: 41; en donde el dominio de enlace CD3 comprende una región pesada variable (VH) humanizada y una región ligera variable (VL) humanizada y en donde la región VH humanizada y la región VL humanizada comprende regiones de marco; en donde la región VH comprende la SEQ ID NO: 28, y la región VL comprende la SEQ ID NO: 34 o una secuencia de aminoácidos de aproximadamente 90% a menos de 100% idéntica a la SEQ ID NO: 34; en donde la región VL comprende una CDR1 qu3 tiene una secuencia de SEQ ID NO: 52, una región CDR2 que tiene una secuencia de SEQ ID NO. 53, y una CDR3 que tiene una secuencia de SEQ ID NO: 54, y en don del polipéptido de enlace CD3 comprende además un segundo dominio de enlace.
MX2014012578A 2012-04-20 2013-04-18 Polipeptidos de enlace cd3. MX366813B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15
PCT/US2013/037135 WO2013158856A2 (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Publications (2)

Publication Number Publication Date
MX2014012578A MX2014012578A (es) 2015-05-11
MX366813B true MX366813B (es) 2019-07-25

Family

ID=49384230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012578A MX366813B (es) 2012-04-20 2013-04-18 Polipeptidos de enlace cd3.

Country Status (16)

Country Link
US (1) US10202452B2 (es)
EP (1) EP2839019A4 (es)
JP (2) JP6509724B2 (es)
KR (1) KR20150004856A (es)
CN (1) CN104487587A (es)
AU (2) AU2013249267A1 (es)
BR (1) BR112014025830A8 (es)
CA (1) CA2870545A1 (es)
HK (2) HK1207398A1 (es)
IL (1) IL235093B (es)
IN (1) IN2014MN02293A (es)
MX (1) MX366813B (es)
RU (1) RU2673153C2 (es)
SG (2) SG11201406346SA (es)
UA (1) UA119227C2 (es)
WO (1) WO2013158856A2 (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
MX2016009653A (es) 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MY191964A (en) 2015-01-23 2022-07-21 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6921001B2 (ja) 2015-04-13 2021-08-18 ファイザー・インク Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
JP7340221B2 (ja) * 2015-05-01 2023-09-07 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア グリカン依存性免疫療法分子
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MX2018003292A (es) * 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
US20170096485A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
PT3461261T (pt) * 2016-05-20 2025-07-31 Harpoon Therapeutics Inc Proteínas de ligação ao cd3 de fragmento variável de cadeia única
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
CN106146661A (zh) * 2016-06-17 2016-11-23 中山大学 抗cd3单域抗体
CN106084046A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106117359A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106117360A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084047A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084049A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106117361A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084048A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
CN106146662A (zh) * 2016-07-18 2016-11-23 中山大学 抗cd3单域抗体
HRP20240767T1 (hr) * 2016-09-14 2024-09-13 Teneoone, Inc. Cd3 vezujuća antitijela
US11242400B2 (en) 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CA3086665A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019160904A1 (en) 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
US20210269525A1 (en) * 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
US11530274B2 (en) 2018-07-02 2022-12-20 Amgen Inc. Anti-STEAP1 antigen-binding protein
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CA3110706A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
US12258405B2 (en) * 2018-12-07 2025-03-25 Jiangsu Hengrui Medicine Co., Ltd. CD3 antibody and pharmaceutical use thereof
WO2020168555A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
AU2020252556B2 (en) 2019-04-05 2026-02-05 Teneobio, Inc. Heavy chain antibodies binding to PSMA
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
JP2023512446A (ja) 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
CA3170330A1 (en) 2020-02-21 2021-08-26 Macrogenics, Inc. Cd137 binding molecules and uses thereof
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
CA3218661A1 (en) 2020-04-04 2022-11-17 David Campbell Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
CA3182697A1 (en) 2020-05-11 2021-11-18 Janssen Biotech, Inc. Methods for treating multiple myeloma
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
JP2023529853A (ja) * 2020-06-17 2023-07-12 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー キメラ抗原受容体（ｃａｒ）ｔ細胞療法を増強するための組成物および方法
MX2023000839A (es) * 2020-07-20 2023-04-18 Zymeworks Bc Inc Proteinas de fusion que comprenden un par ligando-receptor y una proteina biologicamente funcional.
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CA3198102A1 (en) * 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
EP4314056A1 (en) * 2021-03-24 2024-02-07 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
CN117255800A (zh) * 2021-04-28 2023-12-19 恩格姆生物制药公司 具有抗体恒定区变体的结合分子的多聚化
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
US20240254241A1 (en) * 2021-05-11 2024-08-01 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
KR20240099376A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
CN115232213B (zh) * 2022-07-19 2025-08-15 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
PT1489097E (pt) 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0922111B1 (en) 1996-07-23 2004-12-01 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
DK1049787T3 (da) 1998-01-23 2005-04-04 Vlaams Interuniv Inst Biotech Antistofderivater med flere anvendelsesmuligheder
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US7521054B2 (en) 2000-11-17 2009-04-21 The United States Of America As Represented By The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point
RU2179862C1 (ru) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ZA200606410B (en) 2004-02-16 2007-12-27 Micromet Ag Less immunogenic binding molecules
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
IN2014DN10515A (es) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
WO2007145941A2 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US20100056759A1 (en) 2006-10-19 2010-03-04 Tolerx, Inc. Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations
WO2008079713A2 (en) 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
CA2691819A1 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP2012531885A (ja) 2008-07-02 2012-12-13 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｉｌ６免疫治療剤
WO2010003108A2 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
WO2010014629A1 (en) 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
BRPI0919382A2 (pt) 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
BRPI0920749A8 (pt) 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EA032828B1 (ru) 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG181952A1 (en) * 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
KR101308922B1 (ko) * 2012-02-15 2013-09-23 주식회사 경동나비엔 연소기기용 듀얼 벤츄리
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides

Also Published As

Publication number Publication date
EP2839019A2 (en) 2015-02-25
SG10201608307WA (en) 2016-11-29
IN2014MN02293A (es) 2015-08-07
MX2014012578A (es) 2015-05-11
IL235093B (en) 2019-09-26
WO2013158856A2 (en) 2013-10-24
AU2013249267A1 (en) 2014-10-23
RU2014142166A (ru) 2016-06-10
CN104487587A (zh) 2015-04-01
BR112014025830A8 (pt) 2017-10-10
BR112014025830A2 (es) 2017-06-20
KR20150004856A (ko) 2015-01-13
US20150232557A1 (en) 2015-08-20
SG11201406346SA (en) 2014-11-27
JP2018138039A (ja) 2018-09-06
CA2870545A1 (en) 2013-10-24
AU2017228643B2 (en) 2019-12-05
JP6509724B2 (ja) 2019-05-08
JP2015521032A (ja) 2015-07-27
UA119227C2 (uk) 2019-05-27
EP2839019A4 (en) 2016-03-30
HK1207398A1 (en) 2016-01-29
US10202452B2 (en) 2019-02-12
AU2017228643A1 (en) 2017-10-05
IL235093A0 (en) 2014-12-31
HK1208707A1 (en) 2016-03-11
RU2673153C2 (ru) 2018-11-22

Similar Documents

Publication Publication Date Title
MX366813B (es) Polipeptidos de enlace cd3.
MX366303B (es) Pirrolobenzodiazepinas y conjugados de las mismas.
IN2014DN09160A (es)
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
ZA201504478B (en) Immunotherapy with binding agents
PH12014502398B1 (en) Pesticidal compositions and processes related thereto
UY34817A (es) Tienopirimidinas
GB201210770D0 (en) Novel conjugation reagents
IN2014MN02276A (es)
ZA201408213B (en) Anti-transglutaminase 2 antibodies
NZ630549A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
EP2820030A4 (en) INTERLEUKIN-3-POLYPEPTIDE CONJUGATES AND ITS USES
IN2012DE02272A (es)
MY151659A (en) Photopolymerizable Resin Composition
GB2491544A (en) Perpetum mobile
IN2012DE01204A (en) "shikhar technology"
UA79072U (en) (4-tert-butylperoxy-4-methylpentyl)methacrylate
GB201221202D0 (en) Phone wobbler 2
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA80811U (en) ETHYL 3-(3,4-DIMETHYLPHENYL)-6-THIOXO-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE
AU345138S (en) Picnic table
GB201216335D0 (en) He ain't heavy II
AU342240S (en) Skewers
GB201001840D0 (en) Stereoscopic teleconference

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: REG LIFE SCIENCES, LLC

FG Grant or registration